CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...
Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. AstraZeneca and Ionis add an EU green light to ...
Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...
Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...
Optum Rx, is the pharmacy benefit manager owned by UnitedHealth Group Inc’s UNH Also Read: HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is ...
Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry. For pharmaceutical companies, especially those with a market cap above $50 billion, year-over ...
Along with partner Vertex Pharmaceuticals, it has won regulatory approval for Casgevy, a revolutionary treatment for SCD and beta-thalassemia. Meanwhile, Intellia is partnered with Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results